Results 111 to 120 of about 4,697 (156)

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. [PDF]

Adv Ther
Shadman M, Munir T, Xu S, Yang K, Mohseninejad L, Guthrie G, Hirata J, Lefebure M, Williams R, Tam CS.   +9 more
europepmc   +1 more source

Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data. [PDF]

Hematol Rep
Messori A, Gasperoni L, Del Bono L, Damuzzo V.   +3 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study. [PDF]

Br J Haematol
Zelmat Y, Ysebaert L, Gautier P, Sommet A, Lafaurie M, Despas F.   +5 more
europepmc   +1 more source

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Clinical trials indicate that acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, is safe and effective for treating patients with chronic lymphocytic leukemia (CLL), but real-world evidence on its clinical effectiveness is limited. This
Helen Marr (7802549), Stella Williams (7198829), Piers Em Patten (24329117), Anna Morris (8733180), Nimish Shah (7674590), Meghna Ruparelia (24329120), Christopher JC Knechtli (24329138), Francesco Forconi (517485), Betina T Blak (24329153), Alison Boden (24329111), Joy Galani (24329144), Nicolás Martínez-Calle (24329105), Sukhjit Hunjan (24329150), Joe Hickey (12310406), Chris Gregory (3558536), Renata Walewska (497329), Tobore Gbemre (24329132), Mohsen Norouzi (24329108), David L Tucker (17952194), Neil Phillips (627148), Tan Tsawayo (24329126), Mari Kilner (24329114), Helen Wardle (24329129), David J Allsup (7802594), Jenni Davies (24329141), Toby A Eyre (8206989), Claire Hutchinson (2603839), Hannah Harding (24329147), Harriet Walter (20341047), Sharon Oddy (24329123), Shankara Paneesha (8119058), Lucy BM Cook (24329135)   +31 more
core  

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up. [PDF]

Blood Adv
Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR.   +18 more
europepmc   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +1 more source

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. [PDF]

Cureus
Singh M, Podder D, Jacoby AP, Saha S, Chatterji S, Ghosh S, Chattopadhyay D, Kumar J, Nag A, Javed R, Rath A, Chakraborty S, Demde R, Ghosh P, Parihar M, Zameer L, Goel G, Bhattacharya S, Majumder P, Chandy M, Nair R.   +20 more
europepmc   +1 more source

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. [PDF]

Blood Neoplasia
Eken JA, Havenaar FRM, de Groen RAL, Quinten E, Mei H, Sepúlveda-Yáñez JH, Navarrete MA, Drexler HG, Vermaat JSP, van Bergen CAM, Veelken H.   +10 more
europepmc   +1 more source

Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]

J Clin Med
Tedeschi A, Barocelli F, Gerra L, Breviario F, Sbarra F, Pagnoni G, Marasacchia G, Marangi F, Darroudi S, Di Spigno F, Coppi F, Arcari A, Losi G, Vallisa D, Niccoli G, Aschieri D, Navazio A, Tarantini L.   +17 more
europepmc   +1 more source